B-cell overexpression of Bcl-2 cooperates with p21 deficiency for the induction of autoimmunity and lymphomas by Iglesias, Marcos et al.
  
B-cell overexpression of Bcl-2 cooperates with p21 deficiency for the 
induction of autoimmunity and lymphomas 
Inés Santiuste1, Luis Buelta2, Marcos Iglesias1,3, Fernanda Genre1,3, Francisco Mazorra4, 
Shozo Izui5, Jesús Merino1 and Ramón Merino1,3. 
1Departmento de Biología Molecular, Instituto de Formación e Investigación Marqués 
de Valdecilla and 2Departmento de Ciencias Médicas y Quirúrgicas, Universidad de 
Cantabria, Santander, Spain; 3Instituto de Biomedicina y Biotecnología de 
Cantabria/CSIC-Universidad de Cantabria-IDICAN, Santander, Spain; 4Departmento de 
Anatomía Patológica, Hospital Universitario Marqués de Valdecilla, Santander, Spain; 
5Department of Pathology and Immunology, Faculty of Medicine, University of 
Geneva, Geneva, Switzerland. 
 
 
 
 
Correspondence: Dr. Ramón Merino, IBBTEC, Departamento de Biología Molecular, 
Facultad de Medicina, Cardenal Herrera Oria s/n, 39011 Santander, Spain  
Phone: 4 942 201956 
Fax: 34 942 201945 
e-mail: merinor@unican.es 
 
Abstract 
Genetic abnormalities predisposing to autoimmunity generally act in a 
cooperative manner affecting one or several mechanisms regulating immunological 
tolerance. In addition, many of these genetic abnormalities are also involved in the 
development of lymphoproliferative diseases. In the present study, we have determined 
the possible cooperation between deficiencies in members of the Cip/Kip family of cell 
cycle regulators (p21WAF1/Cip1 or p27kip1) and the overexpression of human Bcl-2 in B 
lymphocytes in the induction of autoimmune and lymphoproliferative diseases in non-
autoimmune C57BL/6 (B6) mice. Unlike single mutant mice, B6.p21-/- mice transgenic 
for human Bcl-2 in B cells developed a lethal autoimmune syndrome characterized by 
the production of autoantibodies, the prominent expansion of memory B and CD4+ T 
cells and the development of severe glomerular lesions resembling IgA nephropathy. 
Furthermore, these mice presented a high incidence of B-cell lymphoproliferative 
disorders. Such genetic cooperation in the induction of autoimmunity was not observed 
in B6.p27-/- mice transgenic for human Bcl-2 in B cells. Altogether, what we have 
demonstrated here is the existence of preferential interactions among particular 
regulators of the G1/S transition of the cell cycle and B cell survival in the induction of 
systemic autoimmune and lymphoproliferative diseases. 
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Abreviations: Transgenic mice (Tg), human Bcl-2 (hBcl-2), systemic lupus 
erythematosus (SLE), C57BL/6 (B6), p21WAF1/Cip1 (p21), p27kip1 (p27), autoantibodies 
(autoAbs), lymphoproliferative disorders (LPD), B6-SV40-E-hbcl-2-22 Tg mice (B6-
hBcl-2-B Tg), B6.129S2-Cdkn1atm1Tyj/J (B6.p21-/-), B6.129S4-Cdkn1btm1Mlf/J (B6.p27-/-
), carboxyfluorescein diacetate succinimidyl ester (CFSE), bromodeoxyuridine (BrdU), 
gp70 anti-gp70 immune complexes (gp70 IC), wild type (wt), polymorphic LPD 
(PLPD), activation-induced cell death (AICD). 
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1. Introduction 
With rare exceptions, the development of autoimmune diseases requires the 
contribution of multiple genetic, epigenetic and environmental factors. These factors 
generally act in a cooperative manner affecting one or several mechanisms that regulate 
the induction and maintenance of immunological tolerance [1]. Among the best 
characterized genetic alterations involved in the development of autoimmunity, are 
those that affect the regulation of lymphocyte survival. Using a line of transgenic (Tg) 
mice overexpressing human Bcl-2 (hBcl-2) in B lymphocytes, we and others have 
demonstrated that Tg mice bearing a pro-autoimmune genetic background develop a 
lethal autoimmune lupus-like syndrome that is dependent on the activity of CD4+ 
lymphocytes [2, 3]. However, the overexpression of hBcl-2 in B cells from C57BL/6 
(B6) mice, which do not have a genetic predisposition to developing the disease, fails to 
promote autoimmune manifestations [2], indicating that the inhibition of B lymphocyte 
apoptosis by itself is not sufficient to trigger a severe autoimmune reaction. Similarly, 
B6 mice deficient in bim or Fas fail to develop a fatal autoimmune pathology in contrast 
to the severe systemic lupus erythematosus (SLE) observed in mixed (129/Sv x B6)-
bim−/− or MRL.Faslpr mice, respectively [4-6]. 
The deregulation in the control of lymphocyte proliferation is also associated 
with the development of autoimmune diseases. In this sense, mice deficient in 
p21WAF1/Cip1 (p21; a member of the Cip/Kip family of cell cycle inhibitors) in a line of 
mice with a mixed (129/Sv x B6) genetic background (derived from 2-3 intercrosses) 
develop a fatal lupus-like syndrome that affects females more than males [7]. Similarly, 
the administration of a peptidyl mimic of p21 into (NZB x NZW)F1 females 
significantly reduces the severity of the spontaneous SLE in these animals [8]. Again, 
the severity of the autoimmune syndrome in p21-/- mice appears to be modulated by the 
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genetic background of the mice analyzed. Thus, B6 and BXSB mice deficient in p21 or 
an additional line of p21-/- mixed (129/Sv x B6) mice, derived from an unknown number 
of intercrosses, are largely protected from the development of SLE [9-12]. Another 
member of the Cip/Kip family acting as a negative regulator of cell cycle is p27kip1 
(p27). Studies have shown that p27 plays an important role in the induction and 
maintenance of clonal anergy of T lymphocytes induced after inhibition of co-
stimulation [13]. In anergic CD4+ T lymphocytes, p27 inhibits the phosphorylation of 
Smad-3 resulting in an increase of the inhibitor of Cdks, p15. Consequently, the 
deficiency in p27 prevents the induction of clonal anergy in T lymphocytes [14]. 
However, p27-/- mice do not develop evident autoimmune manifestations [15]. 
In addition to their ability to promote autoimmunity in the context of a particular 
genetic predisposition, the cell cycle and apoptotic regulators mentioned above may be 
also involved in tumor development. In this regard, Bcl-2 was initially identified as a 
gene implicated in the t(14:18) chromosomal translocation found in the majority of 
follicular B-cell lymphomas [16] and Tg mice overexpressing Bcl-2 in B cells 
spontaneously developed plasmacytomas or immunoblastic B-cell lymphomas albeit 
with a low incidence [17, 18]. Similarly, an association between Burkitt’s lymphomas 
and mutations in p21 that diminish the functional activity of this cell cycle regulator has 
been reported in humans [19], and p21-/- mice have a higher incidence of different types 
of tumours, including B-cell lymphomas, in aged but not young mice [20]. More 
recently, it has been shown that p27-/- mice overexpressing Bcl-2 in T lymphocytes 
spontaneously develop T-cell lymphomas with a high incidence [21]. 
Based on these findings, in the present study we have determined the possible 
cooperation between p21 or p27 deficiency and the B-cell overexpression of Bcl-2 in 
the development of both lupus-like autoimmune disease and B-cell malignancies in 
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normal B6 mice. Our results show that B6.p21-/- mice transgenic for hBcl-2 in B cells 
(B6.p21-/--hBcl-2-B Tg) developed a lethal lupus-like syndrome characterized by the 
production of autoantibodies (autoAbs), the increase in memory B and CD4+ T cells and 
the presence of severe glomerular lesions resembling an IgA nephropathy. In addition, 
these mice exhibited a high incidence of B-cell lymphoproliferative disorders (LPD). 
On the other hand, the deficiency in p27 failed to promote autoimmune responses in 
B6.hBcl-2-B Tg mice, indicating the existence of preferential interactions among 
particular regulators of the G1/S transition of the cell cycle and cell survival for the 
control of B-cell tolerance.  
 
2. Materials and methods 
2.1. Mice 
 B6 mice were obtained from Harlan Iberica (Barcelona, Spain). B6-SV40-E-
hbcl-2-22 Tg mice (B6-hBcl-2-B Tg) [3] overexpressing hBcl-2 in B cells, B6.129S2-
Cdkn1atm1Tyj/J (B6.p21-/-) [22] and B6.129S4-Cdkn1btm1Mlf/J (B6.p27-/-) mice [15] were 
purchased from The Jackson Laboratories (Bar Harbor, ME). The selection of hBcl-2-B 
Tg mice was performed by flow cytometry using peripheral blood mononuclear cells 
and a specific mAb against hBcl-2 (clone 6C8; BD Biosciences, Madrid, Spain), as 
described previously [23]. B6.p21-/--hBcl-2-B Tg and B6.p27-/--hBcl-2-B Tg mice were 
obtained by intercrossing F1 progeny of B6.p21-/- and B6.p27-/- mice with B6-hBcl-2-B 
Tg mice. The p21 and p27 genotyping of the different strains of mice was performed by 
PCR. Male and female mice of each mouse strain were analyzed together. The mice 
were bled every two months from the retro-orbital plexus, and the resulting sera were 
stored at –20oC until used.  
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All studies with live animals were approved by the Universidad de Cantabria 
Institutional Laboratory Animal Care and Use Committee. 
 
2.2. Cell death and in vitro proliferation assays 
To analyze the possible modulation of hBcl-2 anti-apoptotic activity in B cells 
by p21 or p27 deficiency in vivo, 2 month-old mice of the different strains used here 
were injected ip. with 2 mg of dexamethasone sodium phosphate (American Regent 
Laboratories, Shirley, NY). The numbers of pre-B (B220lowIgM-) and immature B 
(B220lowwIgM+) cells in the bone marrow were analyzed 48 hrs later by flow cytometry. 
Purified B cells (more than 95% purity in all cases) from different strains of mice 
were obtained from the spleen after in vitro treatment with anti-Thy-1.2 mAb (clone 
AT-83, a rat IgM anti-mouse Thy-1.2 mAb) and complement (Cedarlane Laboratories, 
Hornby, ON, Canada). The effects of hBcl-2 overexpression on B cell survival in vitro 
in the different lines of hBcl-2 Tg mice and non-Tg controls were assessed using 
purified cell populations cultured with RPMI medium supplemented with 2mM L-
glutamine, 10-5 M 2-mercaptoethanol and 10% heat-inactivated FCS (Hyclone 
Laboratories, Logan, UT), as described previously [24]. 
B-cell labelling with carboxyfluorescein diacetate succinimidyl ester (CFSE, 
Molecular Probes Europe, Leiden, The Netherlands) was performed according to the 
manufacturer’s instructions. For in vitro proliferation assays, 2 x 105 CFSE-labelled B 
cells from the different strains of mice were stimulated during 48 hrs with LPS or an 
affinity-purified F(ab')2 goat anti-mouse IgM polyclonal Ab (Jackson ImmunoResearch 
Laboratories, Inc., West Grove, PA), at concentrations of 20 g/ml. Cell division was 
analyzed by flow cytometry according to the CFSE intensity dilution. 
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2.3. Flow cytometry studies 
 The number of total B220, B220+IgM-IgD-CD138- (memory phenotype), naïve 
CD4+CD44lowCD62Lhigh, CD4+CD44highCD62Llow (memory phenotype), naïve 
CD8+CD44lowCD62Lhigh and CD8+CD44highCD62Llow (memory phenotype) cells in the 
spleen of the different strains of mice was evaluated by flow cytometry at 2 and 8 
months of age. Single cell suspensions were stained with different combinations of 
flourescein isothiocyanate-, phycoerythrin-, peridinin chlorophyll protein- and biotin-
conjugated mAbs (BD Biosciences) followed by allophycocyanin-conjugated 
streptavidin. A total of 5 x 104 viable cells were analyzed in a FACSCanto II flow 
cytometer using FACSDiva software (BD Biosciences). 
 
2.4. Serological studies 
 Serum levels of total IgA and IgG were determined by ELISA as described 
previously [2, 25]. Results were expressed in mg/ml in reference to a standard curve 
obtained with a mouse reference serum (ICN Biomedicals Inc.). The presence of IgG 
and IgA anti-DNA autoAbs was determined in sera by ELISA as described [2, 25] and 
the results expressed in TU in reference to a standard curve obtained from a serum pool 
from 6-8 months old MRL lpr/lpr mice. Serum levels of IgG gp70 anti-gp70 immune 
complexes (gp70 IC) were quantified by ELISA [26] and the results expressed as g of 
Ab-bound gp70/ml of serum.  
 
2.5. Histopathology 
 Samples of all major organs were obtained at autopsy. Organs were included in 
paraffin and stained with hematoxilin-eosin or Masson trichrome for pathological 
studies. Glomerulonephritis was scored on a 0 to 4 scale as previously described [27]. 
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Grades 3 and 4 glomerulonephritis were considered significant contributors to clinical 
disease and/or death. The incidence of B-cell LPD in the different mouse strains was 
analyzed at 8-10 and 18 months of age by histology, immunohistochemistry and flow 
cytometry. All histological preparations were analyzed blinded by one (kidney sections) 
or two (B-cell LPD) pathologists.  
 Tissue-bound IgG and IgA antibodies were studied by immunofluorescence on 
kidney cryosections using FITC-conjugated goat anti-mouse IgG antibodies (Jackson 
ImmunoResearch) or FITC-conjugated goat anti-mouse IgA antibody (Cappel 
Laboratories, Cochranville, PA). 
 
2.6. Statistical analysis 
 Statistical analysis of differences between groups of mice was performed using 
the Mann-Whitney test. Probability values <0.05 were considered significant. 
 
3. Results 
3.1. Lack of the effect of p21 deficiency on the survival and proliferation of B cells 
overexpressing hBcl-2 
 We first determined whether p21 deficiency modulated the anti-apoptotic 
activity of hBcl-2 in B cells from B6.p21-/--hBcl-2-B Tg mice, as p21 can act as a 
survival factor in several cell types including T lymphocytes [reviewed in 28]. After the 
viability of purified B cells in culture had been assessed during a period of 10 days, B 
cells from both B6.hBcl-2-B Tg and B6.p21-/--hBcl-2-B Tg mice exhibited a similarly 
improved survival as compared to B cells from B6-wt and B6.p21-/- mice (Figure 1A). 
The lack of the effect of p21 deficiency on B-cell survival was confirmed in vivo after 
induction of apoptosis of pre-B and immature B cells with glucocorticoids. The 
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injection of dexamethasone into B6-wt and B6.p21-/- mice induced the elimination of 
about 85% of B220lowIgM- pre-B and 80% B220lowIgM+ immature B cells in the bone 
marrow (Figure 1B). These two B-cell precursors were, however, largely preserved in 
dexamethasone-treated B6.hBcl-2-B Tg mice and this protection was not modified in 
B6.p21-/--hBcl-2-B Tg mice (Figure 1B). 
 It has been reported that the overexpression of Bcl-2 has an anti-proliferative 
effect in lymphocytes [29, 30]. Accordingly, the in vitro proliferation of B lymphocytes 
from B6.hBcl-2-B Tg mice 48 hrs after stimulation with anti-IgM antibodies or LPS 
was lower than that observed with B cells from B6-wt mice (Figure 1C). Although an 
increased in vitro anti-IgM- or LPS-induced B-cell proliferation was observed in 
B6.p21-/- mice, the p21 deficiency was not sufficient to rescue the proliferative defect 
induced by Bcl-2 overexpression in B cells from B6.p21-/--hBcl-2-B Tg mice (Figure 
1C).  
 
3.2. Effects of B-cell overexpression of hBcl-2 in p21-/- mice in the development of 
autoimmunity 
We next compared the development of a lupus-like autoimmune disease between 
B6-wt, B6.p21-/-, B6.hBcl-2-B Tg and B6.p21-/--hBcl-2-B Tg mice by analyzing the 
levels of circulating autoAbs at 6 months of age. A significant increase in serum levels 
of IgA and IgG anti-ssDNA autoAbs was observed in B6.hBcl-2-B Tg mice in 
comparison to B6-wt and B6.p21-/- mice (p<0.01 in all cases), while levels of 
nephritogenic gp70 IC were essentially identical in these three strains of mice (Figure 
2A). In contrast, B6.p21-/--hBcl-2-B Tg mice exhibited 2-4-fold higher levels of anti-
ssDNA and gp70 IC than B6.hBcl-2-B Tg mice (Figure 2A; p<0.005 in all the cases). In 
addition, analysis of serum levels of IgA and IgG also revealed significant increases of 
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IgA in B6.hBcl-2-B Tg mice, as compared with B6-wt and B6.p21-/- mice (p<0.01), and 
of both IgA and IgG in B6.p21-/--hBcl-2-B Tg mice, as compared with B6.hBcl-2-B Tg 
mice (p<0.005), (Figure 2B).  
We compared by flow cytometry the distribution of B and T cell populations in 
spleens between B6-wt, B6.p21-/-, B6.hBcl-2-B Tg and B6.p21-/--hBcl-2-B Tg mice at 2 
and 8 months of age. As expected, mice overexpressing hBcl-2 in B cells displayed a 
marked accumulation of B cells in B6.hBcl-2-B and B6.p21-/--hBcl-2-B Tg mice (Table 
1). The size of B cells with a memory phenotype (B200+IgM-IgD-CD138-) was greatly 
enlarged in 2 and 8 month-old B6.hBcl-2-B Tg mice (p<0.01 and p<0.001, respectively) 
and modestly increased in B6.p21-/- mice at 8 months of age (p<0.05; Table 1). The 
combination of Bcl-2 overexpression and p21 deficiency appeared synergistic as the 
number of B200+IgM-IgD-CD138- B cells in B6.p21-/--hBcl-2-B Tg mice was highly  
increased (p<0.05 at 2 months and p<0.001 at 8 months; Table 1). As reported in mixed 
(129/Sv x B6) mice deficient in p21 [7], an age-dependent expansion in CD4+ T cells 
with a memory phenotype (CD4+CD44highCD62Llow) was observed in B6.p21-/- mice 
(p<0.05; Table 1). Such an expansion was more pronounced in B6.p21-/--hBcl-2-B Tg 
mice (p<0.005) and already evident at 2 months of age, which was not the case in 
B6.hBcl-2-B Tg mice (Table 1). No differences were observed in the numbers of naïve 
and memory CD8+ T cells among these strains of mice.  
In correlation with the production of autoAb and the expansion of B200+IgM-
IgD-CD138- B and CD4+CD44highCD62Llow T cells, B6.p21-/--hBcl-2-B Tg mice had a 
reduced lifespan in comparison to B6-wt, B6.p21-/- and B6.hBcl-2-B Tg mice (Figure 
3). In fact, 50% of B6.p21-/--hBcl-2-B Tg mice died at around 16 months of age 
(p<0.001). When examined for the cause of death, 52% (22/42) of B6.p21-/--hBcl-2-B 
Tg mice (p<0.001) showed at the time of autopsy a severe glomerulonephritis (Figure 
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4A) characterized by an intense mesangial matrix expansion, secondary to collagen 
accumulation (stained in blue with the Masson trichrome) that completely collapsed the 
capillary spaces (glomerulosclerosis) (Figure 4B). By direct immunofluorescence, 
prominent deposits of IgA, but not of IgG, were detected in the glomerular mesangium 
of these animals (Figure 4B). None of the B6-wt, B6.p21-/- and B6.hBcl-2-B Tg mice 
examined showed severe glomerular lesions at 14-16 months of age (Figure 4A and B). 
Altogether, our results indicated the development of an IgA nephropathy associated to 
SLE in B6.p21-/--hBcl-2-B Tg mice. Unlike mice deficient in p21 in a mixed (129/Sv x 
B6) genetic background which developed a lupus-like syndrome that affects females 
more than males [7], no differences in the levels of circulating autoAbs, memory B and 
CD4+ T cell expansion, development of glomerulonephritis and mortality rate were 
observed between both sexes of B6.p21-/--hBcl-2-B Tg mice (data not shown). 
 
3.3. Absence of a severe SLE in B6.p27-/--hBcl-2-B Tg mice 
We further explored whether the deficiency of p27, another regulator of the G1/S 
transition of cell cycle, also cooperates with hBcl-2 overexpression in B cells for the 
induction of autoimmunity mice. As observed in p21-/- mice, the deficiency in p27 failed 
to modify the survival of B cells and the anti-apoptotic activity of Bcl-2 in vitro and in 
vivo (Figure 1A and B). In addition, the analysis for the effects of p27 deficiency in the 
proliferation of hBcl-2 overexpressing B cells showed that the reduced proliferation of 
B cells in mice overexpressing hBcl-2 was not restored by p27 deficiency (Figure 1C).  
When the production of autoAbs in B6.p27-/- mice at 6 months of age was 
analyzed, only the levels of circulating total IgA and IgG were slightly increased or 
reduced, respectively, in comparison to B6-wt and B6.p21-/- mice (Figure 2; p<0.02 in 
all cases). The levels of circulating IgA and IgG anti-ssDNA autoAbs in B6.p27-/--hBcl-
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2-B Tg mice were significantly elevated as compared to B6.p27-/- mice (p<0.005 in all 
cases), but not higher than those of B6.hBcl-2-B Tg mice and much lower than those of 
B6.p21-/--hBcl-2-B Tg mice (Figure 2; p<0.002 in all cases). The pool of B200+IgM-
IgD-CD138- B cells was increased in the spleen of 8 month-old B6.p27-/- and 2 and 8 
month-old B6.p27-/--hBcl-2-B Tg mice in comparison to B6-wt mice, but was still lower 
than that of B6.p21-/--hBcl-2-B Tg mice at both 2 and 8 months of age (Table 1; p<0.01 
in both cases). Furthermore, B6.p27-/- and B6.p27-/--hBcl-2-B Tg mice also displayed an 
increase in the number of CD4+CD44highCD62Llow T cells at levels similar to that 
observed in B6.p21-/--hBcl-2-B Tg mice (Table 1). The analysis of renal histopathology 
at 14 months of age in B6.p27-/- and B6.p27-/--hBcl-2-B Tg mice revealed that only 13% 
of B6.p27-/- (3/22) and B6.p27-/--hBcl-2-B Tg mice (3/23) developed a severe 
glomerulonephritis (Figure 4A and C). 
 
3.4. Development of B-cell LPD in B6.p21-/--hBcl-2-B Tg mice 
Since almost half of B6.p21-/--hBcl-2-B Tg mice did not show severe glomerular 
lesions at the time of autopsy, we explored for the presence of additional causes of death 
in these animals. In fact, B6.p21-/--hBcl-2-B Tg mice presented an elevated incidence of 
B-cell LPD, evaluated by histological analysis (Figure 5 and Table 2) and 
immunohistochemistry and/or flow cytometry (data not shown). These malignancies 
were classified into two histological categories; polymorphic LPD (PLPD) composed of 
B cells at different stages of development/activation (small cells, immunoblasts and 
plasma cells) (Figure 5A and B) and monomorphic LPD resembling immunoblastic B–
cell lymphomas (Figure 5C and D) showing signs of high proliferative activity such as 
abundant aberrant mitosis (Figure C) and a starry sky pattern (Figure 5D), indicative of 
the presence of macrophages phagocyting dying cells. These lymphomas usually 
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formed solid peritoneal tumours and infiltrated other organs such as the liver or kidneys 
(Figure 5D). Some animals displayed only PLPD but the majority of mice with B-cell 
lymphomas also had PLPD usually in the infiltrating organs (Figure 5D and E). 
To analyze in greater detail the development of LPD in B6.p21-/--hBcl-2-B Tg 
mice in comparison to B6-wt, B6.p21-/- and B6.hBcl-2-B Tg mice, groups of these 
animals were sacrificed at 8-10 months and 18 months of age. At 8-10 months of age 
31% and 44% of B6.p21-/--hBcl-2-B Tg mice presented PLPD and B-cell lymphomas, 
respectively, in contrast to 7% of B6.p21-/- mice presenting PLPD (Table 2). None of 
B6-wt and B6.hBcl-2-B Tg mice had B-cell malignancies at this age. Among the 
B6.p21-/--hBcl-2-B Tg mice that survived up to 18 months of age, 15% and 70% of 
animals presented PLPD and B-cell lymphomas, respectively (Table 2). In contrast, the 
respective incidences were 19% and 2% in B6.p21-/- mice, and 0% and 17% in B6.hBcl-
2-B Tg mice.  
 
4. Discussion 
 The control of cell cycle and survival is essential for the maintenance of 
lymphoid homeostasis and self-tolerance. Disruption in the regulation of any of these 
processes in mice can lead to autoimmunity and/or LPD [1]. However, the development 
of pathology in these animals, particularly autoimmune diseases, is largely influenced 
by the genetic background of the strains of mice studied [2, 9-12]. Due to the 
polygenetic nature of autoimmune diseases, we have analyzed here the possible 
complementation between genetic defects affecting the regulation of lymphocyte 
survival (Bcl-2 overexpression) and proliferation (p21 or p27 deficiency) in the 
development of autoimmunity and LPD in mice with a non-autoinmune genetic 
background. We have demonstrated that the deficiency in the cell cycle regulator p21 
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and the overexpression of Bcl-2 in B cells in non-autoimmune B6 mice promote a lethal 
lupus-like syndrome characterized by autoAb production and an IgA nephropathy. This 
lupus-like syndrome associated to IgA nephropathy resembles that of (NZW x B6)F1 
mice overexpressing hBcl-2 in B cells [2], supporting the importance of B-cell Bcl-2 
deregulation in the pathogenesis of this particular form of experimental 
glomerulonephritis. In addition, B6.p21-/--hBcl-2-B Tg mice present a high incidence of 
B-cell LPD. In contrast, such cooperation for the development of autoimmunity is not 
observed in p27-/- mice overexpressing Bcl-2 in B cells. 
 Our present results confirm the importance of the pro-autoimmune genetic 
predisposition for the complete manifestation of autoimmunity in mice deficient in p21. 
Recently, it has been shown that B6.p21-/- mice develop mild lupus-like serological and 
glomerular abnormalities that do not modify the lifespan of these animals in comparison 
to mice deficient in p21 in an autoimmune-prone mixed (129/Sv x B6) genetic 
background [7, 9]. This contrasts with the lack of development of even a mild lupus-like 
syndrome in our B6.p21-/- mice, and the reasons for this discrepancy may be attributed 
to differences in animal housing conditions or to the origin of B6 colonies used in both 
studies. However, the fact that B6.p21-/--hBcl-2-B Tg mice develop a severe lupus-like 
syndrome clearly supports the idea that p21 deficiency acts as an autoimmunity 
enhancer that cooperates with hBcl-2 overexpression in B cells, thereby triggering 
severe autoimmune responses in normal mice. The beneficial effects of the treatment 
with a peptidyl mimic of p21, which inhibits the interaction between cyclin-dependent 
kinase 4 and type D cyclins, on the development of SLE in (NZB x NZW)F1 females 
[8] further support this idea. In contrast, other studies in BXSB mice or in a line of p21-/- 
mixed (129/Sv x B6) mice, derived from an unknown number of intercrosses, claim that 
p21 deficiency may have irrelevant or even protective effects on disease development 
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[10-12], suggesting the existence of unknown strain-specific genetic interactions that 
modulate the accelerator activity of this genetic abnormality in autoimmunity. 
 There are multiple evidences indicating that p27 is an important regulator of 
clonal anergy of T lymphocytes [13, 14]. In this sense, p27 is required for 
transplantation tolerance induced by costimulatory blockade [31]. However, p27-/- mice 
have failed to develop autoimmune diseases even in a (129/Sv x B6) genetic 
background [15]. Accordingly, we have been unable to demonstrate the presence of 
high titres of circulating autoAbs and glomerulonephritis in almost all B6.p27-/--hBcl-2-
B Tg mice analyzed here, despite an expansion in memory B and T cells being observed 
in these animals. Recent studies have shown the presence of increased serum levels of 
autoAbs and mild glomerular lesions in B6.hBcl-2-B Tg mice deficient in the G1/S cell 
cycle regulators E2F1 or E2F2, although the survival of these animals is similar to that 
of non-Tg controls [32, 33]. Altogether, these and our present results indicate that the 
regulators of the G1/S transition of the cell cycle are hot spot targets for the control of 
lymphocyte tolerance. However, not all the regulators of this critical cell cycle check 
point appear to influence lymphocyte tolerance to the same extent, there existing a 
certain hierarchy in which each genetic defect of these regulators exhibits different 
potentials to promote systemic autoimmune diseases in cooperation with genetic 
abnormalities that prolong B cell survival (at least Bcl-2 overexpression). In this 
hierarchy, the pro-autoimmune potential of p21deficiency in cooperation with B-cell 
hBcl-2 overexpression is higher than that of E2F1 or E2F2 deficiency, which in turn is 
superior to that of p27 deficiency.  
 In addition to its anti-apoptotic activity, Bcl-2 is also involved in the control of 
cellular proliferation. In particular, the overexpression of Bcl-2 in lymphocytes or 
fibroblasts significantly delays the cell cycle entry of these cells after activation [29, 
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30]. On the other hand, p21 may act as a survival factor in several cell types, including 
T lymphocytes [28]. Thus, epistatic interactions between p21 deficiency and Bcl-2 
overexpression affecting the survival and/or proliferation of B cells can be involved in 
the induction of severe autoimmunity in B6.p21-/--hBcl-2-B Tg mice. However, the anti-
apoptotic and anti-proliferative effects of hBcl-2 overexpression in B cells from 
B6.hBcl-2-B Tg mice are not modified by the presence of the p21 null mutation, 
indicating a dominant role of overexpressed Bcl-2 over p21 deficiency. Although p27 
has been proposed as a critical mediator of the anti-proliferative function of Bcl-2 [30], 
our experiments clearly show that the proliferative defects observed in B cells 
overexpressing hBcl-2 are not restored by p27 deficiency. These results are fully in 
agreement with a recent report showing a similar cell cycle delay in anti-CD3 
stimulated T cells from hBcl-2-T Tg and p27-/--hBcl-2-T Tg mice [21]. However, as our 
studies have been carried out on total B-cell populations, we cannot exclude the 
possibility that the interaction between p21 deficiency and Bcl-2 overexpression 
implicated in cell cycle progression and survival may be restricted to some minor 
subsets of activated/memory B cells (see below).  
 Consistent with a previous finding [7], our B6.p21-/- mice exhibited an age-
dependent enlargement of memory CD4+ T-cell subpopulation, and this is more 
pronounced in B6.p21-/--hBcl-2-B Tg mice developing a severe SLE. However, we 
observed that non-autoimmune B6.p27-/- and B6.p27-/--hBcl-2-B Tg mice had increased 
numbers of CD4+CD44highCD62Llow T cells even at 2 months of age and at levels 
comparable to those of B6.p21-/--hBcl-2-B Tg mice. These data strongly suggest that the 
expansion of these memory T cells in B6.p21-/--hBcl-2-B Tg mice by itself is not 
sufficient to promote the disease.  
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It has been demonstrated that Bcl-2 overexpression extends the lifetime of 
memory B cells [34]. Accordingly, high numbers of B220+IgM-IgD-CD138- memory B 
cell are found in B6.hBcl-2-B Tg mice even at 2 months of age. Parallel to the increase 
in memory CD4+ T cells, memory B cells are also expanded in B6.p21-/- and B6.p27-/- 
mice. However, whereas the size of this B cell population in B6.p27-/--hBcl-2-B Tg 
mice is similar to that of B6.hBcl-2-B Tg mice, a synergistic interaction between p21 
deficiency and Bcl-2 overexpression seems to regulate the number of memory B cells in 
B6.p21-/--hBcl-2-B Tg mice. This synergistic interaction may operate at two levels. 
First, and as in T cells [9], p21 can affect the proliferation of memory, but not naïve, B 
cells that survive activation-induced cell death (AICD) processes. Second, hBcl-2 
overexpression can modulate the pro-apoptotic activity of Bim regulating the survival of 
memory B and autoAb-forming cells during AICD in vivo [35, 36]. In this scenario, the 
abnormal expansion and/or survival of these B cells together with the increased number 
of memory CD4+ T cells may be the cause for the induction of SLE in B6.p21-/--hBcl-2-
B Tg mice. 
A careful analysis of B6.p21-/--hBcl-2-B Tg mice at the time of autopsy indicates 
that in addition to the development of a lupus-like autoimmune syndrome associated 
with an IgA nephropathy, these mice present B-cell LPD with a much higher incidence 
than B6.p21-/- or B6.hBcl-2-B Tg mice. Histologically, these LPD can be classified as 
PLPD and immunoblastic B-cell lymphomas. The coexistence of both types of LPD in 
many animals strongly suggests that these lesions may represent different stages of the 
same B-cell malignancy. Despite the absence of autoimmunity in B6.p27-/--hBcl-2-B Tg 
mice (present study), we have observed the development of B-cell LPD in these animals 
that shortened their lifespan (Santiuste I. et al, manuscript in preparation). In this regard, 
it has been shown that p27-/- mice overexpressing Bcl-2 in T lymphocytes 
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spontaneously develop T-cell lymphomas with a high incidence [21]. At present, the 
mechanisms responsible for the development of B-cell LPD in B6.p21-/--hBcl-2-B Tg 
mice are unknown. One possibility is that the same epistatic interaction between p21 
deficiency and Bcl-2 overexpression promotes LPD in B6.p21-/--hBcl-2-B Tg mice 
independently of the autoimmune syndrome, as both B6.p21-/- or B6.hBcl-2-B Tg mice 
develop with age B-cell malignancies without overt autoimmune diseases [16, 17, 19]. 
Additionally and/or alternatively, the development of B-cell LPD in B6.p21-/--hBcl-2-B 
Tg mice may be closely linked to the autoimmune process, secondary to the chronic 
activation of autoreactive B lymphocytes by non-tolerized CD4+ T cells. In this regard, 
the spontaneous development of B-cell lymphomas is common in different lupus-prone 
mice, such as NZB, Fas or FasL deficient and interleukin-12 receptor beta2 deficient 
mice [37-40]. Experiments are in course to clarify this important question. 
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Figure Legends 
Figure 1. Survival and proliferation of B cells from B6 mice overexpressing hBcl-2 in 
B cells and deficient in p21 or p27. A) Purified B cells from different strains of mice 
were cultured in triplicates in 96-well flat-bottomed plates at a concentration of 106 
cells/ml in RPMI 10% FCS. From day 1 to 10, viability of spleen B cells was assessed 
by trypan blue exclusion. Results are representative of two separate experiments. B) 2 
month-old mice were injected ip with PBS (upper panels) or 2 mg of dexamethasone 
(lower panels). The elimination of B220lowIgM- pre-B and B220lowIgM+ immature B 
cells was evaluated by flow cytometry 48 hrs after treatment. The mean ± SD of the 
percentages of B220lowIgM- pre-B (upper left) and B220lowIgM+ immature B cells 
(bottom right) in the different experimental groups (3 mice/group) are indicated in each 
panel. Statistic differences between hBcl-2 Tg and non-Tg dexamethasone-treated 
animals are indicated as follow: *p<0.01, **p<0.001. Results are representative of three 
separate experiments. C) CFSE-labelled B cells (2 x 105) from the different strains of 
mice were stimulated during 48 hrs with 20 g/m LPS or 20 g/ml of anti-IgM 
antibody. Cell division was analyzed by flow cytometry according to the CFSE intensity 
dilution. Results, representative of two separate experiments, are expressed as the mean 
percentage ± SD (3 mice/group) of proliferating cells. 
 
Figure 2. Production of autoAbs in B6 mice overexpressing hBcl-2 in B cells and 
deficient in p21 or p27. A and B) Serum levels of IgA and IgG anti-DNA autoAbs and 
gp70 IC (A) and of total IgA and IgG (B) in the mentioned mouse strains at 6 months of 
age. Values of individual mice are expressed. Bars represent the mean value of each 
examination.  
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Figure 3. Mortality curve of B6 mice overexpressing hBcl-2 in B cells and deficient in 
p21. 
Figure 4. Development of glomerulonephritis in B6 mice overexpressing hBcl-2 in B 
cells and deficient in p21 or p27. A) Glomerulonephritis score in the different strains of 
mice at the time of autopsy (B6.p21-/--hBcl-2-B Tg mice) or at 14-16 months of age 
(other groups). Values of individual mice are expressed. Bars represent the mean value 
of each group. B) Representative histological appearance of glomeruli (x40) from B6-
wt, B6.p21-/- and B6.hBcl-2-B Tg mice at 14-16 months of age and from B6.p21-/--hBcl-
2-B Tg mice at the time of autopsy, stained with hematoxilin-eosin or Masson trichrome 
(two upper panels). Presence of IgG and IgA deposits (two lower panels) in the 
glomeruli of B6-wt, B6.p21-/- and B6.hBcl-2-B Tg mice at 14-16 months of age and 
from B6.p21-/--hBcl-2-B Tg mice at the time of autopsy (x40). C) Representative 
histological appearance of glomeruli (x40) from 14 month-old B6.p27-/- and B6.p27-/--
hBcl-2-B Tg mice stained with hematoxilin-eosin or Masson trichrome. 
 
Figure 5. Development of LPD in B6 mice overexpressing hBcl-2 in B cells and 
deficient in p21. A) PLPD in a lymph node from a 10 month-old B6.p21-/--hBcl-2-B Tg 
mice (x40). B) PLPD in the lymph node of a 10 month-old B6.p21-/- mice (x40). C) 
Immunoblastic B–cell lymphoma in a 14 month-old B6.p21-/--hBcl-2-B Tg mice (x100) 
showing an aberrant mitosis (red arrow and squared amplification in the bottom left 
corner). D) Starry sky pattern of the immunoblastic B–cell lymphoma showed in B 
(x20). E) PLPD infiltrates in the kidney of an 18 month-old B6.p21-/--hBcl-2-B Tg mice 
(x40). F) Immunoblastic B–cell lymphoma in the lymph node of a 18 month-old 
B6.hBcl-2-B Tg mice (x40) showing areas with PLPD (red arrows).  
 
Table 1: Distribution of naïve and memory B and CD4+ T cell populations in p21 and p27 deficient mice in the context of hBc-2 B-cell 
overexpression. 
   B Cells   CD4+ Cells   CD8+ Cells  
Mice Age B220+  memory naïve  memory naïve  memory 
B6-wt 2 36.4 ± 8.9  2.3 ± 0.5 10.8 ± 4.9  5.3 ± 1.1 7.9 ± 3.2  1.8 ± 0.3 
 8 57.1 ± 10.5  4.9 ± 2.4 11.9 ± 5.3  8.1 ± 1.5 11.6 ± 5.9  2.1 ± 1.8 
B6.p21-/- 2 44.1 ± 17.1  3.9 ± 1.9 11.3 ± 4.8  8.3 ± 4.1 7.9 ± 3.1  1.9 ± 1.5 
 8 35.6 ± 15.4  7.1 ± 3.1 6.4 ± 2.8  14.1 ± 3.9 6.4 ± 2.7  2.2 ± 1.0 
B6.hBcl-2-B Tg 2 166.8 ± 56.5  16.8 ± 6.8 14.1 ± 3.2  6.5 ± 1.0 13.1 ± 3.2  2.1 ± 0.9 
 8 138.8 ± 66.2  22.8 ± 8.4 14.8 ± 5.4  10.1 ± 3.7 14.5 ± 6.3  2.8 ± 1.8 
B6.p21-/--hBcl-2-B Tg 2 206.4 ± 42.8  31.1 ± 9.3 12.2 ± 5.6  15.1 ± 7.7 11.1 ± 3.3  3.9 ± 1.1 
 8 220.6 ± 38.5  41.5 ± 10.1 7.6 ± 3.7  22.5 ± 7.8 7.8 ± 4.2  3.4 ± 1.4 
B6.p27-/- 2 66.2 ± 12.9  4.4 ± 2.2 19.9 ± 8.2  18.1 ± 8.2 23.1 ± 7.1  5.9 ± 3.4 
 8 104.5 ± 39.3  17.3 ± 6.1 7.2 ± 3.4  18.4 ± 5.7 8.3 ± 3.7  5.4 ± 2.3 
B6.p27-/--hBcl-2-B Tg 2 137.7 ± 50.1  16.4 ± 7.5 23.4 ± 4.6  21.9 ± 8.1 28.4 ± 6.3  6.2 ± 1.8 
 8 116.6 ± 32.8  29.2 ± 7.1 5.1 ± 2.7  23.8 ± 8.9 6.0 ± 2.3  6.7 ± 2.7 
 
Total B220+, B200+IgM-IgD-CD38- memory, CD4+CD44lowCD62Lhigh naïve, CD4+CD44highCD62Llow memory, CD8+CD44lowCD62Lhigh naïve 
and CD8+CD44highCD62Llow memory cells were evaluated in the spleen of 2 and 8 month-old mice by flow cytometry. Results from 6-8 
mice/group are expressed as the mean ± SD of the number of cells of each population.  
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Table 2: Increased incidence of B-cell malignancies in B6.p21-/--hBcl-2-B 
Tg mice. 
Mice Type 8-10 months 18 months 
 
B6-wt PLPD 0/16 (0 %) 0/12 (0 %) 
 B-cell lymphoma 0/16 (0 %) 0/12 (0 %) 
B6.p21-/- PLPD 1/14 (7.1 %) 8/43 (18.6 %) 
 B-cell lymphoma 0/14 (0 %) 1/43 (2.3 %) 
B6.hBcl-2-B Tg PLPD 0/18 (0 %) 0/24 (0 %) 
 B-cell lymphoma 0/18 (0 %) 4/24 (16.7 %) 
B6.p21-/--hBcl-2-B PLPD 5/16 (31.3 %) 4/26 (15.4 %) 
 B-cell lymphoma 7/16 (43.8 %) 18/26 (69.2 %) 
Groups of the different mouse strains were sacrificed at 8-10 and 18 months 
of age. Sections of major organs were included in paraffin and stained with 
hematoxilin-eosin. The presence of LPD, either PLPD or B-cell lymphoma, 
was evaluated by two pathologists. Under the PLPD group, we included 
animals that presented only this type of LPD. Under the B-cell lymphoma 
group, we included animals that presented this type of LPD independently 
of the coexistence of PLPD. 
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